|Bid||125.34 x 1100|
|Ask||125.41 x 900|
|Day's range||124.62 - 125.87|
|52-week range||78.90 - 130.08|
|Beta (3Y monthly)||0.62|
|PE ratio (TTM)||44.38|
|Earnings date||30 Oct 2019 - 4 Nov 2019|
|Forward dividend & yield||0.66 (0.53%)|
|1y target est||131.58|
Zoetis Inc. (ZTS) today announced that the European Commission has granted marketing authorisation for Simparica Trio™ (sarolaner/moxidectin/pyrantel) chewable tablets, a once-monthly triple combination antiparasitic medication for dogs with, or at risk from, mixed external and internal parasitic infestations. The granting of the marketing authorisation follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use on July 18, 2019.
Lescault, 43, who enrolled Moose in a clinical trial of an experimental drug designed to help his immune system fight his cancer, represents the type of pet lover that has spurred animal health companies around the globe to invest in developing complex new treatments previously reserved for humans. Biotechnology, which produces medicines from living cells, revolutionized the drug industry more than a quarter century ago with breakthrough medicines at prices that now run as high as hundreds of thousands of dollars a year.
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Triple combination product contains sarolaner, moxidectin and pyrantel
Zoetis Inc. (ZTS) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 19, 2019, in London, England. Clint Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics, will represent the company and respond to questions from analysts.
On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.
Zoetis Inc. (ZTS) will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, Sept. 10, 2019, in New York, N.Y. Glenn David, Executive Vice President and Chief Financial Officer, and Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, will represent the company and respond to questions from analysts. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses.
Zoetis Inc. (ZTS) today announced the completion of the acquisition of Platinum Performance, a privately-held nutrition-focused animal heath company, after fulfilling all closing requirements. The acquisition was first announced on July 22 and financial terms of the transaction are not being disclosed. “We are pleased to welcome the Platinum Performance team to Zoetis and together expand on the success of their high-quality, nutritional product formulas for horses, dogs and cats,” said Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy for Zoetis.
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.